Literature DB >> 27424807

Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.

Edward W Roberts1, Miranda L Broz1, Mikhail Binnewies1, Mark B Headley1, Amanda E Nelson1, Denise M Wolf2, Tsuneyasu Kaisho3, Dusan Bogunovic4, Nina Bhardwaj5, Matthew F Krummel6.   

Abstract

Intratumoral dendritic cells (DC) bearing CD103 in mice or CD141 in humans drive intratumoral CD8(+) T cell activation. Using multiple strategies, we identified a critical role for these DC in trafficking tumor antigen to lymph nodes (LN), resulting in both direct CD8(+) T cell stimulation and antigen hand-off to resident myeloid cells. These effects all required CCR7. Live imaging demonstrated direct presentation to T cells in LN, and CCR7 loss specifically in these cells resulted in defective LN T cell priming and increased tumor outgrowth. CCR7 expression levels in human tumors correlate with signatures of CD141(+) DC, intratumoral T cells, and better clinical outcomes. This work identifies an ongoing pathway to T cell priming, which should be harnessed for tumor therapies.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  2-photon imaging; anti-tumor T cell priming; antigen presentation; antigen trafficking; dendritic cells; draining lymph node; melanoma; tumor; tumor immune response

Mesh:

Substances:

Year:  2016        PMID: 27424807      PMCID: PMC5374862          DOI: 10.1016/j.ccell.2016.06.003

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  39 in total

1.  Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss.

Authors:  Yaroslava Ruzankina; Carolina Pinzon-Guzman; Amma Asare; Tony Ong; Laura Pontano; George Cotsarelis; Valerie P Zediak; Marielena Velez; Avinash Bhandoola; Eric J Brown
Journal:  Cell Stem Cell       Date:  2007-06-07       Impact factor: 24.633

2.  Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.

Authors:  Miranda L Broz; Mikhail Binnewies; Bijan Boldajipour; Amanda E Nelson; Joshua L Pollack; David J Erle; Andrea Barczak; Michael D Rosenblum; Adil Daud; Diane L Barber; Sebastian Amigorena; Laura J Van't Veer; Anne I Sperling; Denise M Wolf; Matthew F Krummel
Journal:  Cancer Cell       Date:  2014-10-16       Impact factor: 31.743

Review 3.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

4.  Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases.

Authors:  A K Indra; X Warot; J Brocard; J M Bornert; J H Xiao; P Chambon; D Metzger
Journal:  Nucleic Acids Res       Date:  1999-11-15       Impact factor: 16.971

5.  CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens.

Authors:  Kenichi Asano; Ami Nabeyama; Yasunobu Miyake; Chun-Hong Qiu; Ai Kurita; Michio Tomura; Osami Kanagawa; Shin-ichiro Fujii; Masato Tanaka
Journal:  Immunity       Date:  2010-12-30       Impact factor: 31.745

6.  Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.

Authors:  Michael A Curran; James P Allison
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

7.  CCR7 mediates directed growth of melanomas towards lymphatics.

Authors:  Maxine S Emmett; Silvia Lanati; Darryl B A Dunn; Oliver A Stone; David O Bates
Journal:  Microcirculation       Date:  2011-04       Impact factor: 2.628

8.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors.

Authors:  Mark S Diamond; Michelle Kinder; Hirokazu Matsushita; Mona Mashayekhi; Gavin P Dunn; Jessica M Archambault; Hsiaoju Lee; Cora D Arthur; J Michael White; Ulrich Kalinke; Kenneth M Murphy; Robert D Schreiber
Journal:  J Exp Med       Date:  2011-09-19       Impact factor: 14.307

9.  T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse.

Authors:  Amy E Moran; Keli L Holzapfel; Yan Xing; Nicole R Cunningham; Jonathan S Maltzman; Jennifer Punt; Kristin A Hogquist
Journal:  J Exp Med       Date:  2011-05-23       Impact factor: 14.307

10.  Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes.

Authors:  Menna R Clatworthy; Caren E Petrie Aronin; Rebeccah J Mathews; Nicole Y Morgan; Kenneth G C Smith; Ronald N Germain
Journal:  Nat Med       Date:  2014-11-10       Impact factor: 53.440

View more
  321 in total

Review 1.  TGFβ biology in cancer progression and immunotherapy.

Authors:  Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal:  Nat Rev Clin Oncol       Date:  2020-07-24       Impact factor: 66.675

2.  TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer.

Authors:  Álvaro de Mingo Pulido; Alycia Gardner; Shandi Hiebler; Hatem Soliman; Hope S Rugo; Matthew F Krummel; Lisa M Coussens; Brian Ruffell
Journal:  Cancer Cell       Date:  2018-01-08       Impact factor: 31.743

Review 3.  Dysfunction of antigen processing and presentation by dendritic cells in cancer.

Authors:  Joanna Bandola-Simon; Paul A Roche
Journal:  Mol Immunol       Date:  2018-04-05       Impact factor: 4.407

Review 4.  Dendritic cells in cancer: the role revisited.

Authors:  Filippo Veglia; Dmitry I Gabrilovich
Journal:  Curr Opin Immunol       Date:  2017-02-10       Impact factor: 7.486

Review 5.  FOXOs in cancer immunity: Knowns and unknowns.

Authors:  Youcai Deng; Fangjie Wang; Tiffany Hughes; Jianhua Yu
Journal:  Semin Cancer Biol       Date:  2018-01-05       Impact factor: 15.707

6.  The liposome of trehalose dimycolate extracted from M. bovis BCG induces antitumor immunity via the activation of dendritic cells and CD8+ T cells.

Authors:  Masanobu Shiga; Jun Miyazaki; Kozaburo Tanuma; Yoshiyuki Nagumo; Takayuki Yoshino; Shuya Kandori; Hiromitsu Negoro; Takahiro Kojima; Ryota Tanaka; Naoko Okiyama; Yasuhiro Fujisawa; Miyuki Watanabe; Sho Yamasaki; Hideyasu Kiyohara; Makoto Watanabe; Taka-Aki Sato; Hideaki Tahara; Hiroyuki Nishiyama; Ikuya Yano
Journal:  Cancer Immunol Immunother       Date:  2021-02-11       Impact factor: 6.968

Review 7.  Studying interactions between dendritic cells and T cells in vivo.

Authors:  Aleksey Chudnovskiy; Giulia Pasqual; Gabriel D Victora
Journal:  Curr Opin Immunol       Date:  2019-03-15       Impact factor: 7.486

8.  A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.

Authors:  Hayley S Ma; Bibhav Poudel; Evanthia Roussos Torres; John-William Sidhom; Tara M Robinson; Brian Christmas; Blake Scott; Kayla Cruz; Skylar Woolman; Valerie Z Wall; Todd Armstrong; Elizabeth M Jaffee
Journal:  Cancer Immunol Res       Date:  2019-01-14       Impact factor: 11.151

Review 9.  Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer.

Authors:  Taylor T Chrisikos; Yifan Zhou; Natalie Slone; Rachel Babcock; Stephanie S Watowich; Haiyan S Li
Journal:  Mol Immunol       Date:  2018-03-15       Impact factor: 4.407

10.  Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine.

Authors:  Bijan Boldajipour; Amanda Nelson; Matthew F Krummel
Journal:  JCI Insight       Date:  2016-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.